• Characterizing Long COVID: Deep Phenotype of a Complex Condition 

      Deer R.R., Rock M.A., Vasilevsky N., Carmody L., Rando H., Anzalone A.J., Basson M.D., Bennett T.D., Bergquist T., Boudreau E.A., Bramante C.T., Byrd J.B., Callahan T.J., Chan L.E., Chu H., Chute C.G., Coleman B.D., Davis H.E., Gagnier J., Greene C.S., Hillegass W.B., Kavuluru R., Kimble W.D., Koraishy F.M., Köhler S., Liang C., Liu F., Liu H., Madhira V., Madlock-Brown C.R., Matentzoglu N., Mazzotti D.R., McMurry J.A., McNair D.S., Moffitt R.A., Monteith T.S., Parker A.M., Perry M.A., Pfaff E., Reese J.T., Saltz J., Schuff R.A., Solomonides A.E., Solway J., Spratt H., Stein G.S., Sule A.A., Topaloglu U., Vavougios G.D., Wang L., Haendel M.A., Robinson P.N. (2021)
      Background: Numerous publications describe the clinical manifestations of post-acute sequelae of SARS-CoV-2 (PASC or “long COVID”), but they are difficult to integrate because of heterogeneous methods and the lack of a ...
    • Infliximab therapy for patients with active and refractory spondyloarthropathies at the dose of 3 mg/kg: A 20-month open treatment 

      Cherouvim, E. P.; Zintzaras, E.; Boki, K. A.; Moutsopoulos, H. M.; Manoussakis, M. N. (2004)
      Background: Infliximab at the dose of 5 mg/kg per infusion has been shown effective for the treatment of active spondyloarthropathies. It is not clear if the 5 mg/kg is required in most patients. Objective: To evaluate the ...
    • Safety of home-based cardiac rehabilitation: A systematic review 

      Stefanakis M., Batalik L., Antoniou V., Pepera G. (2022)
      Background: Cardiac rehabilitation is an evidence-based intervention that aims to improve health outcomes in cardiovascular disease patients, but it is largely underutilized. One strategy for improving utilization is ...